Jeito Capital — Full Portfolio

Alentis is a biotech company developing therapies for chronic liver disease, fibrosis, and cancer based on the molecular biology of liver disease.

AI & Machine LearningBiotechHealthtechMedical DevicesBasel, CH

Thomas Baumert(Founder)inMark Pruzanski(Chief Executive Officer)inLuigi Manenti(Chief Medical Officer)inJon Freve(Chief Financial Officer)inBryan Yoon(General Counsel and Chief Administrative Officer)inAditya Venugopal(Chief Business Officer)in

Co-investorsAvego BioScience CapitalBioMedPartnersFrazier Life SciencesLongitude CapitalNovo HoldingsOrbiMed+5 more

Aviceda is a company that presents itself as backed by a range of investors, but the page provides no concrete details about its products or business area.

BiotechDigital HealthHealthtechMedical Devices

Mohamed A. Genead(Chairman & CEO)inJeffrey Nau(Chief Executive Officer)inTarek S. Hassan(Chief Development Officer)in

Co-investorsLongitude CapitalOrbiMedDigitalis Ventures

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.

BiotechDeep TechHealthtechMedical DevicesLeiden, NL

Hans Aerts(Professor)Hermen Overkleeft(Professor)Stan van Boeckel(Professor)

Co-investorsBioMedPartnersForbionBioGeneration VenturesPictet GroupSeroba Life Sciences

Bionyra Pharma is a clinical-stage biopharmaceutical company developing next-generation mono and multispecific antibodies for severe immune-mediated inflammatory diseases, with an initial focus on atopic dermatitis and inflammatory bowel disease.

BiotechHealthtech

Frédéric Marrache(Co-founder & CEO)in

Co-investorsSanofi VenturesSofinnova PartnersVIVES PartnersApollo Health VenturesSixty Degree Capital

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in

Co-investorsBioqube VenturesForbionBayern KapitalCanaan PartnersNovartis Venture FundBioGeneration Ventures

CDR-Life develops T cell engager immunotherapies for cancer and autoimmune diseases using its M-gager antibody platform, targeting both conventional tumor antigens and hard-to-treat targets.

BiotechHealthtechHorgen, CH

Rouven Bingel-Erlenmeyer(Founder)inChristian Leisner(Co-founder)inDominik Escher(Co-founder)

Co-investorsRA Capital

Corteria Pharma develops interceptive therapies aimed at treating subpopulations of patients with heart failure, sarcopenia, and obesity.

BiotechDigital HealthHealthtechLongevity

Philip JaniakinMarie-Laure OzouxinRégis OlivierinFrancesca C. LawsonMark KowalaEleonore Jouannyin

Co-investorsFountain Healthcare PartnersKurma PartnersOrbiMedV-Bio VenturesOmnes CapitalInvivo Capital Partners+1 more

NMD Pharma is a clinical-stage biotech company developing first-in-class small-molecule therapies that selectively target skeletal muscle to treat rare neuromuscular diseases and age-related conditions.

BiotechDeep TechHealthtechMedical DevicesAarhus, DK

Co-investorsNovo HoldingsRoche Venture FundInkef

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation.

BiotechMedical DevicesCambridge, US

Gary D Glick(Executive Officer, Director)in

BoardJill Carroll(Director)inCarl Gordon(Director)inValerie Odegard(Director)Jeffrey Leiden(Director)Charles Baum(Director)

Board seatKsenija Pavletic· per SEC Form D

Co-investorsActivant CapitalBalderton CapitalCatalio Capital Management, LPForesite CapitalGlobal BioAccess FundGreatPoint Ventures+6 more

Quell Therapeutics is a clinical-stage biopharmaceutical company developing targeted Treg cell therapies with advanced manufacturing capabilities.

BiotechDeep TechHealthtechMedical Devices

Co-investorsAlbionVCSV Health InvestorsUCL Technology Fund

Adcendo develops antibody-drug conjugates (ADCs) engineered to treat cancers with high unmet medical needs.

BiotechDigital HealthMedical Devices

Co-investorsVida VenturesYsios Capital

Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.

BiotechMedical Devices

Co-investorsVida VenturesHealthCapNovo HoldingsOrbiMedPontifax Venture CapitalRA Capital+2 more

Alveus Therapeutics develops next-generation metabolic and obesity therapies, including its lead asset ALV-100 (in Phase 2) and a preclinical amylin pipeline of peptides, oral small molecules, and novel formats aimed at sustainable weight loss with better tolerability.

BiotechHealthtechLongevityPhiladelphia, US

Raj Kannan(Executive Officer, Director)

BoardClaudio Nessi(Director)inIvan Gergel(Director)inJan Van de Bossche(Director)inGarrett Ingram(Director)Gregory Parekh(Director)

Co-investorsAndera PartnersAvego BioScience CapitalGlobal BioAccess FundNew Rhein Healthcare Investors, LLCSeroba Life SciencesAgent Capital+2 more

Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.

BiotechMedical Devices

Co-investorsAdBio partnersNovo HoldingsPMVV-Bio VenturesAsabys PartnersNewton Biocapital

BiotechCambridge, US

Mohamed Genead(Executive Officer, Director)inMichael Tolentino(Executive Officer, Director)inDavid Callanan(Executive Officer)inTarek Hassan(Executive Officer)inDerek Kunimoto(Executive Officer)in

BoardDavid Guyer(Director)

Co-investorsCatalio Capital Management, LPLongitude Capital

Seattle and Singapore-based biotech developing next-generation multi-payload antibody-drug conjugates for cancer treatment.

Co-investorsClavystBioFrazier Life SciencesNorwest Venture PartnersPureos Bioventures

Callio Therapeutics develops next-generation dual-payload antibody-drug conjugates (ADCs) with differentiated payload and linker technologies for targeted cancer treatment.

BiotechMedical DevicesSeattle, US

Piers Ingram(President, Co-Founder)inJerome Boyd-Kirkup(Chief Scientific Officer, Co-Founder)inZachary Hornby(Chief Executive Officer)

Co-investorsNovo HoldingsOmega FundsFrazier Life SciencesNorwest Venture Partners

Global company developing next-generation eye disease therapies; acquired by Merck & Co.

Co-investorsBain Capital Life SciencesMRL Ventures FundSV Health Investors

EyeBio (Eyebiotech Limited), a subsidiary of Merck, develops therapies for retinal diseases such as diabetic macular edema and neovascular age-related macular degeneration, targeting vascular leakage through pathways like Wnt signaling.

BiotechHealthtechHolborn, London

David R. Guyer(Founder, CEO & President)Anthony P. Adamis(Chief Scientific Officer, Co-founder, Director & Chair of Advisory Board)James Allister John Costine(Director)Michael Jay Ross(Executive Officer)Catherine Elizabeth Bingham(Director)

Biotech company developing antibodies to treat autoimmune and inflammatory diseases.

Co-investorsArkin CapitalMonograph Capital Partners

Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.

BiotechNew York, US

Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)

BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)

Co-investorsEcoR1 CapitalVida VenturesTPG

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

Ilise Lombardo(Chief Executive Officer)inVolker Knappertz(Executive Vice President of Research & Development)inMichael Samar(Chief Financial Officer)inRob Lasser(Chief Medical Officer)in

Co-investorsBioMedPartnersRoche Venture FundSofinnova PartnersEQTEQT Life SciencesForbion+2 more

Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.

BiotechHealthtech

Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin

Co-investorsAdjuvant CapitalF-Prime CapitalLongwood FundSR One Capital ManagementSV Health InvestorsVivo Capital+2 more

ReproNovo develops therapeutic solutions for male and female fertility and women's health conditions like adenomyosis, targeting unmet medical needs in reproductive medicine.

BiotechFemTechHealthtechMedical DevicesLausanne, CH

Co-investorsM VenturesYsios Capital

Develops gene therapy treatments for Inherited Retinal Diseases regardless of genetic cause.

Co-investorsAdBio partners

SparingVision develops neuroprotective gene therapies for rare genetic diseases affecting the eye and nervous system.

BiotechDeep TechDigital HealthMedical Devices

Co-investorsAdBio partnersYsios Capital

XyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage.

BiotechHealthtechMedical DevicesMalvern, US

Ronald Crystal(Co-founder)Todd Rosengart(Co-founder)John Tucker(President and Chief Executive Officer)Albert Gianchetti(Executive Officer, Director)

BoardGlenn Batchelder(Director)James Cohen(Director)

Co-investorsLumira VenturesFountain Healthcare PartnersLongwood FundSofinnova Ventures